How to Get Leqvio (Inclisiran) in New York

What Is Leqvio and Why Does It Matter for High Cholesterol

Leqvio (inclisiran) is a small-interfering RNA (siRNA) that blocks the liver from producing PCSK9, the protein that degrades LDL receptors. By cutting off PCSK9 at the mRNA level, inclisiran lowers LDL-C by roughly 50% with only two maintenance injections per year, after an initial loading schedule. The FDA approved it on December 22, 2021, for adults with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL-C lowering beyond maximally tolerated statin therapy. [1]

The pooled ORION-10 and ORION-11 trials (combined N=3,457) published in the New England Journal of Medicine in 2020 demonstrated a time-averaged LDL-C reduction of 51% (P<0.0001 vs. placebo) at day 510 in patients already on background statin therapy. [2] Injection-site reactions were the most common adverse event, reported in 2.6% of inclisiran patients vs. 1.8% of placebo recipients. That safety profile is one reason New York cardiologists have grown comfortable offering inclisiran to patients who miss doses with monthly or quarterly PCSK9 monoclonal antibodies like evolocumab or alirocumab. [3]

The American College of Cardiology and American Heart Association 2022 Guideline on Cardiovascular Risk Reduction states: "For patients with ASCVD who require additional LDL-C lowering, PCSK9 inhibitors are recommended as add-on therapy to maximally tolerated statins." [4] Inclisiran fits squarely within that recommendation, and its twice-yearly administration schedule reduces adherence barriers compared to subcutaneous monoclonal antibodies dosed every two or four weeks. [5]

Who Qualifies for a Leqvio Prescription in New York

Two FDA-approved indications exist: HeFH and clinical ASCVD. A New York prescriber must document that the patient has one of these diagnoses and that LDL-C remains above goal despite maximum tolerated statin therapy, with or without ezetimibe. [1]

For ASCVD, the standard definition includes prior acute MI, prior stroke, symptomatic peripheral arterial disease, or other major atherosclerotic events. The ACC/AHA guidelines set an LDL-C goal of <70 mg/dL for very high-risk ASCVD patients; most New York insurers use that threshold as the prior-authorization trigger. [4] For HeFH, a diagnosis based on the Dutch Lipid Clinic Network criteria or genetic testing confirming a pathogenic LDL receptor, apolipoprotein B, or PCSK9 variant is generally sufficient for coverage. [6]

Patients with LDL-C <70 mg/dL already controlled on statin plus ezetimibe are unlikely to clear prior authorization without additional documentation of statin intolerance or persistently elevated cardiovascular risk scores. Prescribers should note the ACC's Familial Hypercholesterolemia guidance: "Cascade screening of first-degree relatives is recommended when a proband is diagnosed with FH." [6] Documentation of a family history workup can strengthen a prior-authorization submission.

Age is not a formal contraindication, but inclisiran trials enrolled adults 18 and older. Renal impairment down to an eGFR of 15 mL/min/1.73 m² does not require dose adjustment, a point the FDA label explicitly confirms, making inclisiran accessible to many New York patients with chronic kidney disease who have elevated cardiovascular risk. [1]

Labs Required Before Starting Leqvio in New York

A fasting lipid panel is the minimum required test. Most New York insurers also require two separate LDL-C values above the threshold, typically obtained at least 4 weeks apart, to document persistent elevation before approving inclisiran. [7]

The standard pre-prescription laboratory panel that HealthRX clinicians use for inclisiran evaluations in New York includes:

• Fasting lipid panel (total cholesterol, LDL-C, HDL-C, triglycerides)
• ALT and AST (baseline hepatic function)
• Creatinine and eGFR (to document renal status for the label)
• HbA1c or fasting glucose if metabolic syndrome is suspected
• TSH if the patient has not been tested for hypothyroidism recently (a correctable cause of secondary hypercholesterolemia)

The inclisiran prescribing information does not mandate liver function tests before treatment, but the ACC/AHA guidelines recommend ruling out secondary causes of hypercholesterolemia, and most insurance prior-authorization forms ask for hepatic and renal values. [1][4] TSH testing in particular catches a subset of patients whose LDL-C normalizes after thyroid replacement, sparing them an unnecessary PCSK9 inhibitor. [8]

Lipid labs should be drawn while the patient is on a stable statin dose for at least 4 to 6 weeks. Results from labs completed within 90 days are typically accepted by New York Medicaid managed-care plans for prior-authorization submissions.

How to Get a Leqvio Prescription in New York: Step by Step

Getting a Leqvio prescription in New York follows a clear path. Identify a licensed New York prescriber, complete the required labs, submit or support a prior-authorization request, and arrange for in-office injection. The entire process from first appointment to first injection can take 2 to 6 weeks depending on insurer turnaround times. [9]

Step 1. Choose a prescriber. In New York, physicians (MD, DO), nurse practitioners (NP) with full prescriptive authority, and physician assistants (PA) under a collaborative practice agreement may all prescribe inclisiran. [10] New York NPs have independent prescribing authority under Education Law §6902, which means a cardiologist referral is not required to initiate the prescription chain.

Step 2. Complete baseline labs. Order the fasting lipid panel and supporting labs listed in the section above. Allow 4 to 6 weeks on a stable statin before drawing lipids so results reflect a true treatment-refractory baseline.

Step 3. Confirm the clinical indication. The prescriber documents HeFH or ASCVD in the chart and records that LDL-C remains above goal on maximally tolerated statin therapy. This documentation forms the backbone of the prior-authorization letter.

Step 4. Submit prior authorization. For commercial plans, the prescriber's office submits a PA form with the chart note, lab values, and prior statin trial history. For New York Medicaid, the Preferred Drug Program requires documentation of diagnosis, LDL-C above threshold, and statin optimization before approving non-preferred PCSK9 inhibitors. [11] Turnaround is 3 to 15 business days for standard review.

Step 5. Obtain the drug. Leqvio is distributed through specialty pharmacies, including CVS Specialty, Accredo, and the Novartis Leqvio Patient Services hub. The specialty pharmacy ships directly to the administering clinic or physician office, not to the patient's home.

Step 6. Receive the injection. Inclisiran must be administered by a healthcare provider, not self-injected. The first injection is given in office, the second at 3 months, and maintenance injections every 6 months thereafter. [1]

Telehealth Prescribing for Leqvio in New York

New York telehealth law permits a licensed New York provider to prescribe Schedule II-VI controlled substances and non-controlled medications, including inclisiran, after a synchronous audio-video visit that satisfies the standard of care. Inclisiran is not a controlled substance, so the regulatory bar is lower than for opioids or stimulants. [10]

Under New York Public Health Law §2999-cc, telehealth is defined to include real-time video consultation, store-and-forward transmission, and remote patient monitoring. A prescriber conducting a telehealth visit for inclisiran must still review labs, confirm the indication, and document the visit in a manner consistent with in-person care. [10] The New York State Department of Health reinforced these requirements in its 2023 telehealth guidance. [12]

Practically, this means a New York patient can consult a cardiologist or internist via video, share recent lab results, and receive a Leqvio prescription without an in-person visit. The injection itself still requires a physical visit to a clinic or provider office, because inclisiran cannot be self-administered. Telehealth is therefore most useful for the prescribing and prior-authorization steps, not for injection administration.

Several national telehealth platforms hold New York medical licenses and list inclisiran or PCSK9 inhibitor management among their cardiology services. Patients should verify that the platform's clinicians hold an active New York license through the New York State Office of the Professions license verification tool before scheduling.

The HealthRX inclisiran access framework for New York patients: telehealth visit for workup and prescription (week 1 to 2), prior-authorization submission by the telehealth provider's care coordinator (week 2 to 3), specialty pharmacy shipment to a local infusion partner or primary care office (week 3 to 5), first injection administered in that local office (week 4 to 6). This four-phase pathway keeps the patient from needing to travel to a specialist while still satisfying the in-office injection requirement.

Prior Authorization in New York: What Documentation Insurers Require

Prior authorization is the single biggest bottleneck for inclisiran access in New York. Commercial insurers and Medicaid managed-care organizations each have their own PA criteria, but the documentation checklist is largely consistent across plans.

Standard prior-authorization requirements for Leqvio in New York include: [9][11]

1. Confirmed diagnosis of HeFH or clinical ASCVD (ICD-10 codes E78.01 for HeFH or I25.10 for ISCHD/ASCVD are commonly required)
2. Two fasting LDL-C values above threshold (typically >70 mg/dL for ASCVD, >100 mg/dL for HeFH without prior events)
3. Documentation of current maximally tolerated statin (generic atorvastatin 40 to 80 mg or rosuvastatin 20 to 40 mg preferred)
4. Trial of ezetimibe 10 mg daily (most New York commercial plans require at least a 90-day trial or documented intolerance)
5. Documentation of statin intolerance if maximum dose was not reached (CK levels, myopathy notes, or rechallenge documentation)
6. Letter of medical necessity from the prescribing physician, including cardiovascular risk rationale

The New York State Medicaid Preferred Drug Program lists inclisiran as non-preferred within the PCSK9 inhibitor class as of 2024, meaning prior authorization is required but coverage is available. [11] Empire BlueCross, MVP Health Care, and Fidelis Care are among the major New York plans that have published PA criteria consistent with the checklist above. [9]

Appeals are possible if PA is denied. The prescriber can cite the ORION-10 and ORION-11 data showing 51% LDL-C reduction and a cardiovascular outcomes signal in the concurrent ORION-4 trial, which enrolled 15,000 patients and is ongoing at sites including New York Presbyterian. [2][13]

503A Compounding and Inclisiran in New York

Compounded inclisiran is a legally and clinically distinct product from FDA-approved Leqvio. 503A pharmacies in New York are licensed by the New York State Board of Pharmacy and may compound drug products from bulk active pharmaceutical ingredients for patient-specific prescriptions, but they cannot compound a drug that is a copy of an FDA-approved product without meeting specific criteria under federal law. [14]

The FDA has not placed inclisiran on the 503A bulks list as of mid-2025, meaning 503A pharmacies in New York cannot legally compound inclisiran for routine clinical use. [14] Any advertisement for "compounded inclisiran" from a New York 503A pharmacy should be treated with significant caution. The FDA's position, stated in its compounding guidance documents, is that "pharmacies may not compound drug products that are essentially a copy of a commercially available drug product." [14]

Patients seeking cost-reduction alternatives should instead explore the Novartis Leqvio patient assistance program (Novartis Patient Assistance Foundation) and the Leqvio co-pay card, which reduces out-of-pocket cost to as low as $0 for eligible commercially insured patients. [15] New York Medicaid beneficiaries who obtain prior authorization pay no out-of-pocket cost under standard Medicaid rules.

Cost and Insurance Coverage in New York

The wholesale acquisition cost of Leqvio is approximately $3,300 per injection (roughly $6,600 per year for two maintenance doses). Without insurance, that price places inclisiran out of reach for most patients. [15]

New York commercial insurers typically cover inclisiran under the specialty tier after PA approval. Copays range from $50 to $500 per injection without a manufacturer coupon. The Novartis co-pay card can reduce commercially insured patient costs to $0 per injection for up to 24 months. [15] Patients must not be enrolled in a federal or state government insurance program (Medicare, Medicaid, CHIP) to use the co-pay card.

For Medicare Part B beneficiaries, inclisiran may be covered under Part B (as a provider-administered drug) rather than Part D, because it is injected in a clinical setting. The Centers for Medicare and Medicaid Services issued a national coverage determination analysis for inclisiran in 2023; individual Medicare Advantage plans in New York may have different formulary placements. [16] Patients should call the member services number on their Medicare card to confirm benefit tier before scheduling the first injection.

New York Medicaid covers inclisiran with prior authorization for qualifying diagnoses. The fee-for-service program and most Medicaid managed-care plans (including MetroPlusHealth and HealthFirst) follow the Preferred Drug Program criteria. [11]

How Long Does It Take to Get Leqvio in New York

The realistic timeline from first inquiry to first injection is 2 to 6 weeks for most New York patients. Lab results take 1 to 5 business days. Prior-authorization processing takes 3 to 15 business days under New York Insurance Law, which requires insurers to respond to standard PA requests within 3 business days and urgent requests within 1 business day. [17] Specialty pharmacy shipment to the administering clinic takes 2 to 7 business days after PA approval.

Patients who arrive at their first telehealth or in-person appointment with recent labs (drawn within 90 days) can compress the timeline. A prescriber who submits the PA the same day as the visit can realistically achieve first injection within 2 to 3 weeks. Complex cases requiring peer-to-peer review or appeals extend the timeline by 10 to 20 business days. [17]

After the first injection, the second dose is given at day 90 (3 months). From that point, the maintenance schedule is one injection every 6 months. Patients typically see LDL-C reduction measurable on a lipid panel drawn 3 months after the first dose, consistent with the ORION-10 trial's 30-day LDL-C data showing a 70% reduction at nadir before partial recovery to the steady-state 51% time-averaged reduction. [2]

Transferring an Existing Leqvio Prescription to New York

Patients relocating to New York with an active inclisiran prescription from another state face a two-part process: establishing care with a New York-licensed prescriber and re-verifying insurance coverage under a New York plan.

Inclisiran is not a controlled substance, so there is no federal or state restriction on transferring the prescription itself. However, because inclisiran is a specialty drug distributed through a limited pharmacy network, the practical transfer involves notifying the specialty pharmacy (Accredo, CVS Specialty, or the Novartis hub) of the new administering provider's address in New York. [15]

The transferring prescriber should send chart notes, lab history, and the prior-authorization approval letter to the new New York provider. If the patient's insurance plan has changed, a new prior-authorization submission may be required under the New York plan's criteria even if the previous state's insurer had already approved the drug. New York Medicaid patients moving from other state Medicaid programs should expect a new PA review, as each state's Preferred Drug Program operates independently. [11]

The new New York prescriber must hold a DEA registration (required for any Schedule II-V prescribing and standard for any licensed prescriber) and a valid New York State license. They do not need to be a cardiologist; an internist or NP with independent prescribing authority can maintain the prescription. [10]